NCT06540144 2026-05-08An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia GravisUCB PharmaPhase 3 Enrolling by invitation12 enrolled